欢迎访问qy千亿官网官方网站

图片名

全国订购热线:
18966759382

首页 > 新闻资讯 > 技术资讯

技术资讯
行业新闻 市场活动 技术资讯

CAS:1185054-34-5|Vedaprofen-d3,维达洛芬-d3

作者:QY千亿国际 发布时间:2025-06-06 13:45:33 次浏览

生物活性:Vedaprofen-d3 is the deuterium labeled Vedaprofen. Vedaprofen (Quadrisol) is a COX-1 selective nonsteroidal anti-inflammatory agent (NSAID) for serum TxB2 and exudate PGE2 inhibition [1]. Vedaprofen is a Escherichia coli (E. coli) sliding clamp (SC) inhibitor with the IC50 of 222 μM[2].
体外研究(In Vitro):Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
QY千亿国际 has not independently confirmed the accuracy of these methods. They are for reference only.
Vedaprofen-d3 相关抗体:
COX2 Antibody
COX IV Antibody
COX2/Cyclooxygenase 2 Antibody
COX IV Antibody (YA867)
Cyclooxygenase 1 Antibody (YA2537)
Cyclooxygenase 2 Antibody (YA2541)
分子量:285.40
Formula:C19H19D3O2
CAS 号:1185054-34-5
非标记 CAS:71109-09-6
中文名称:维达洛芬-d3
运输条件:Room temperature in continental US; may vary elsewhere.
储存方式:Please store the product under the recommended conditions in the Certificate of Analysis.
纯度 & 产品资料
Data Sheet (530 KB)
产品使用指南 (1538 KB)
参考文献
[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.
 [Content Brief]
[2]. P Lees, et al. PK-PD integration and PK-PD modelling of nonsteroidal anti-inflammatory drugs: principles and applications in veterinary pharmacology. J Vet Pharmacol Ther. 2004 Dec;27(6):491-502.
 [Content Brief]
[3]. Zhou Yin,et al. DNA replication is the target for the antibacterial effects of nonsteroidal anti-inflammatory drugs. Chem Biol. 2014 Apr 24;21(4):481-487.
 [Content Brief]
[4]. M Hoeijmakers, et al. The pharmacokinetics of Vedaprofen and its enantiomers in dogs after single and multiple dosing. J Vet Pharmacol Ther. 2005 Jun;28(3):305-12.
 [Content Brief]